You are here
Metastatic castration resistant prostate cancer (mCRPC)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial
By Sartor O. Coleman R. Nilsson S. Heinrich D. Helle S.I. O'Sullivan J.M. Fossa S.D. Chodacki A. Wiechno P. Logue J. Widmark A. Johannessen D.C. Hoskin P. James N.D. Solberg A. Syndikus I. Vogelzang N.J. O'Bryan-Tear C.G. Shan M. Bruland T.S. Parker C.The Lancet Oncology, Volume 15, Issue 7, June 2014, Pages 738-746
Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status
Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, Renee Lester, Christian Kollmannsberger, Nevin Murray, Ravinder Clayton, Daniel Y.C. Heng, Anthony M. Joshua, Kim N. Chi
European Urology, Volume 67, Issue 3, Pages 441 - 447
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
By L.R. Molife, A. Omlin, R.J. Jones, V. Karavasilis, D. Bloomfield, G. Lumsden, P.C. Fong, D. Olmos, J.M. O'Sullivan, I. Pedley, T. Hickish, P. Jenkins, E. Thompson, N. Oommen, D. Wheatley, C. Heath, G. Temple, K. Pelling and J.S. de Bono.Future Oncology. Volume 10, Issue 2, February 2014, Pages 219-231.
Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials
By C.J. Morgan, W.K. Oh, G. Naik, M.D. Galsky and G. Sonpavde.Critical Reviews in Oncology/Hematology, Volume 90, Issue 3, June 2014, Pages 253-261.
By F. Zustovich and F. Fabiani.Critical Reviews in Oncology/Hematology, 2014 Article in Press
By N. Gupta, O.A. Ustwani, L. Shen and R. Pili.OncoTargets and Therapy, Volume 7, 12 February 2014, Pages 223-234.
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
By O.B. Goodman, T.W. Flaig, A. Molina, P.F.A. Mulders, K. Fizazi, H. Suttmann, J. Li, T. Kheoh, J.S. De Bono and and H.I. Scher.Prostate Cancer and Prostatic Diseases, Volume 17, Issue 1, March 2014, Pages 34-39.
Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
By M. Shirley and P.L. McCormackDrugs, Volume 74, Issue 5, 2014, Pages 579-586
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naive castration-resistant prostate cancer
By A.A. Azad, E.K. Beardsley, S.J. Hotte, S.L. Ellard, L. Klotz, J. Chin, C. Kollmannsberger, S.D. Mukherjee and and K.N. Chi.Investigational New Drugs 28 March 2014
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
J.S. De Bono, J.M. Piulats, H.S. Pandha, D.P. Petrylak, F. Saad, L.M.A. Aparicio, S.K. Sandhu, P. Fong, S. Gillessen, G.R. Hudes T. Wang, J. Scranton, and M.N. PollakClinical Cancer Research, Volume 20, Issue 7, 1 April 2014, Pages 1925-1934